MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) has announced the development of a language-agnostic artificial intelligence speech model capable of detecting drug and alcohol intoxication across multiple languages. This advancement enables scalable, non-invasive testing for industries requiring high-volume safety screening, such as mining, aviation, construction, and law enforcement.
The AI prediction model leverages over 50 million data points to predict alcohol intoxication with remarkable accuracy using only the human voice. According to the company, the technology is being commercialized as an enterprise platform that includes Edge-AI kiosks integrating bespoke hardware and software for detecting drug and alcohol intoxication in a range of enterprise environments. This innovation could significantly enhance workplace safety by providing real-time, non-invasive testing without the need for blood, breath, or urine samples.
For industries like mining and construction, where operator impairment is a critical safety concern, this technology could reduce accidents and improve compliance. In aviation and law enforcement, rapid and accurate intoxication detection is essential for public safety. The cross-language capability makes the model applicable globally, addressing a key barrier in current testing methods that often rely on language-specific analysis.
The announcement underscores the growing role of AI in safety and health monitoring. By using voice analysis, the technology offers a cost-effective and efficient alternative to traditional testing. The company is developing the platform for deployment in enterprise settings, potentially transforming how organizations manage impairment risk.
For more details, the full press release is available at https://ibn.fm/PfjuT. Additional information about MindBio Therapeutics and its latest updates can be found in the company’s newsroom at https://ibn.fm/MBQIF.
